ASCENT: A Landmark Advance in Treating Refractory Triple-Negative Breast Cancer
In the Phase III trial, sacituzumab govitecan significantly improved progression-free survival and overall survival over standard chemotherapy
Encouraging Long-Term Survival Benefits with Atezolizumab Plus Nab-Paclitaxel in Metastatic Triple-Negative Breast Cancer
Mixed results from IMpassion 130 and IMpassion 131 also draw attention to chemotherapy backbone selection
How is COVID-19 Affecting the Wellbeing of Oncology Professionals?
Dr Susana Banerjee summarises results from two surveys investigating the psychological impact of the pandemic on medical oncologists
Intensive Follow-up Increases Frequency of Curative Intent Secondary Surgery in Colorectal Cancer
Results from the PRODIGE 13 trial, presented at ESMO Virtual Congress 2020, show that optimisation of diagnostic procedures in terms of overall survival benefits remains to be determined
Neoadjuvant Immunotherapy Does Not Find Its Place Yet in Resectable NSCLC
Although disappointing, results from IONESCO and PRINCEPS trials are preliminary
Is Precision Medicine Fulfilling its Promise?
The delivery of precision medicine is still restricted by clinicians’ capability to interpret the genomic alterations and match them with the most appropriate medicines
Dozens of COVID19-Related Articles Retracted: How to Assess the Quality of Research in the COVID-19 Era
Dr Alessandra Curioni-Fontecedro shares her perspectives on the pitfalls of peer reviewing and its impact on the scientific community and the society
Developing National Cancer Control Programmes to Strengthen Health Service Quality Planning
Dr Dario Trapani comments on a study revealing cancer burden projections for 2020 among European Union Member States that provides quality data to formulate informed health policies.
Bringing Innovation to Cancer Patients
Held virtually for the first time this year, ESMO’s annual congress is connecting the oncology community to improve cancer care in the COVID-19 era